Výsledky vyhledávání - "Anna-Maria Barbuti"

MG53 inhibits cellular proliferation and tumor progression in colorectal carcinoma

Autor: Pranav Gupta, Haichang Li, Guan-Nan Zhang, Anna Maria Barbuti, Yuqi Yang, Pei-hui Lin, Chuanxi Cai, Tao Tan, Jianjie Ma, Zhe-Sheng Chen

Publikováno v: International journal of biological sciences. 18(14)

Cancer is the second leading cause of mortality after cardiovascular diseases in the United States. Chemotherapy is widely used to treat cancers. Since the development of drug resistance is a major contributor towards the failure of chemotherapeutic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2adf72701cb61e79a9b0ac37c853a01f
https://pubmed.ncbi.nlm.nih.gov/36147477

Zobrazit plný text záznamu

Lipid–Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo

Autor: Guan-Nan Zhang, Pranav Gupta, Ying-Fang Fan, Yun-Kai Zhang, Charles R. Ashby, Qiaobing Xu, Anna Maria Barbuti, Ming Wang, Zhe-Sheng Chen, Leli Zeng

Publikováno v: Cancers, Vol 12, Iss 2, p 498 (2020)
Cancers
Volume 12
Issue 2

Although the judicious use of anticancer drugs that target one or more receptor tyrosine kinases constitutes an effective strategy to attenuate tumor growth, drug resistance is commonly encountered in cancer patients. The ATP-binding cassette transpo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e265dc4eb7e2859e9316cc8de6827c1
https://www.mdpi.com/2072-6694/12/2/498

Zobrazit plný text záznamu

Plný text ve formátu HTML

Comprehensive Synthesis of Amino Acid-Derived Thiazole Peptidomimetic Analogues to Understand the Enigmatic Drug/Substrate-Binding Site of P-Glycoprotein

Autor: Biebele Abel, Suresh V. Ambudkar, Anna Maria Barbuti, Zhe-Sheng Chen, Bhargav A. Patel, Tanaji T. Talele, Uday Kiran Velagapudi

Publikováno v: Journal of Medicinal Chemistry. 61:834-864

A novel set of 64 analogues based on our lead compound 1 was designed and synthesized with an initial objective of understanding the structural requirements of ligands binding to a highly perplexing substrate-binding site of P-gp and their effect on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::547344ff05923a98dea8fda3d5b1ebf8
https://doi.org/10.1021/acs.jmedchem.7b01340

Zobrazit plný text záznamu

Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib

Autor: Guan-Nan Zhang, Zhe-Sheng Chen, Xin-Yue Yu, Xi-Jun Zhu, John N. D. Wurpel, Ai-Wen Wen, Anna Maria Barbuti, Yi-Jun Wang, Yun-Kai Zhang

Publikováno v: Pharmacological Research. 119:89-98

Cabozantinib (XL184) is a small molecule tyrosine kinase receptor inhibitor, which targets c-Met and VEGFR2. Cabozantinib has been approved by the Food and Drug Administration to treat advanced medullary thyroid cancer and renal cell carcinoma. In th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c70e79a4e66eff8a1823a0074ce13e8d
https://doi.org/10.1016/j.phrs.2017.01.024

Zobrazit plný text záznamu

Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia

Autor: Anna Maria Barbuti, Dong-Hua Yang, Xin Zhang, Pranav Gupta, Jingxuan Pan, Ke Ding, Jingfeng Zhou, Guan-Nan Zhang, Sabesan Yoganathan, Nishant Karadkhelkar, Zhe-Sheng Chen

Publikováno v: Cancer letters. 472

Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm primarily due to the presence of the BCR-ABL fusion gene that produces the constitutively active protein, BCR-ABL. Imatinib, a BCR-ABL-targeted drug, is a first-line drug for the treatme

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d66a139066b3d2d4b21a1ab521bcd88e
https://pubmed.ncbi.nlm.nih.gov/31837444

Zobrazit plný text záznamu

EGFR and HER2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy

Autor: Zhe-Sheng Chen, Silpa Narayanan, Pranav Gupta, Anna Maria Barbuti, Guan-Nan Zhang

Traditional chemotherapy drugs aim to fight cancer cell proliferation, targeting DNA or mechanisms of mitosis. Unfortunately, some chemotherapy drugs fail due to innate or acquired drug resistance. Clinical cancer therapy regimens employ multiple dru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::661a68da50d9050f7a18a618797afc8e
https://doi.org/10.1016/b978-0-12-816435-8.00001-8

Zobrazit plný text záznamu

Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy

Autor: Zhe-Sheng Chen, Anna Maria Barbuti

Publikováno v: Cancers
Cancers, Vol 7, Iss 4, Pp 2360-2371 (2015)

Paclitaxel (Taxol(®)) is a member of the taxane class of anticancer drugs and one of the most common chemotherapeutic agents used against many forms of cancer. Paclitaxel is a microtubule-stabilizer that selectively arrests cells in the G2/M phase o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4ee3c8de51633e66d74552decb8f038
https://doi.org/10.3390/cancers7040897

Zobrazit plný text záznamu

Plasma Anti-Glycan Antibody Profiles Associated with Nickel level in Urine

Autor: Anna-Maria Barbuti, Marko Vuskovic, Bing Yan, Jingping Niu, Laura Glassman, Qingshan Qu, Emma Goldsmith-Rooney, Max Costa, Nicolai V. Bovin, Harvey I. Pass, Meichi Chen, Kam-Meng Tchou-Wong, Margaret E. Huflejt

Publikováno v: Journal of proteomics & bioinformatics

Nickel (Ni) compounds are widely used in industrial and commercial products including household and cooking utensils, jewelry, dental appliances and implants. Occupational exposure to nickel is associated with an increased risk for lung and nasal can

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f19a65c32403aa3252425e509989987
http://europepmc.org/articles/PMC3984841

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání